Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Cardiovascular and kidney outcomes Tirzepatide has cardiovascular outcome data from the SURPASS-CVOT study, which showed favorable effects on major adverse cardiovascular events in people with type 2 diabetes
J Diabetes Investig (2015) 6:2019
Wegovy is licensed in the UK in doses up to 2.4mg for weight loss and, on 14 September 2025, Novo Nordisk published results of a phase IIIb clinical trial (STEP UP, NCT05646706) of a 7.2mg dose of semaglutide for subcutaneous injection 1
Again, this is likely due to an improved blood flow due to a higher nitrate concentration
J Clin Endocrinol Metab, 2025
US$ 29.63
US$ 29.23
US$ 24.30
US$ 23.94
US$ 25.63
